Gefitinib Impurity 35, with the CAS number 861453-12-5, is a chemical compound that is recognized as an impurity associated with the synthesis of gefitinib, a targeted therapy used primarily in the treatment of non-small cell lung cancer. While specific characteristics such as molecular weight, structure, and solubility may vary, impurities like this one are typically characterized by their potential to affect the efficacy and safety of the primary drug. Impurities can arise during the manufacturing process and may influence the pharmacokinetics and pharmacodynamics of the active pharmaceutical ingredient. The identification and quantification of such impurities are crucial in pharmaceutical development to ensure compliance with regulatory standards and to maintain the quality of the final product. Analytical techniques such as high-performance liquid chromatography (HPLC) and mass spectrometry are commonly employed to characterize and monitor impurities in drug formulations. Understanding the properties and behavior of impurities like Gefitinib Impurity 35 is essential for ensuring the safety and effectiveness of gefitinib as a therapeutic agent.

Gefitinib Impurity 35

861453-12-5: Gefitinib Impurity 35, with the CAS number 861453-12-5, is a chemical compound that is recognized as an impurity associated with the synthesis of gefitinib, a targeted therapy used primarily in the treatment of non-small cell lung cancer. While specific characteristics such as molecular weight, structure, and solubility may vary, impurities like this one are typically characterized by their potential to affect the efficacy and safety of the primary drug. Impurities can arise during the manufacturing process and may influence the pharmacokinetics and pharmacodynamics of the active pharmaceutical ingredient. The identification and quantification of such impurities are crucial in pharmaceutical development to ensure compliance with regulatory standards and to maintain the quality of the final product. Analytical techniques such as high-performance liquid chromatography (HPLC) and mass spectrometry are commonly employed to characterize and monitor impurities in drug formulations. Understanding the properties and behavior of impurities like Gefitinib Impurity 35 is essential for ensuring the safety and effectiveness of gefitinib as a therapeutic agent.

CAS 861453-12-5

Gefitinib Impurity 35

Gefitinib Impurity 45

Ref: 4Z-G-2366